Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy

Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy

Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK)/receptor tyrosine kinase inhibitor (ROS1), demonstrated efficacy in ROS1 positive (ROS1+) non-small cell lung cancer (NSCLC), although approval is currently limited to the treatment of ALK+ patients. However, lorlatinib-induced resistan...

Full description

Bibliographic Details
Main Authors: Balázs Jóri, Markus Falk, Iris Hövel, Peggy Weist, Markus Tiemann, Lukas C. Heukamp, Frank Griesinger
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Current Oncology
Subjects:
NSCLC
lorlatinib
ROS1
resistance mutation
liquid biopsy
G2032R
Online Access:https://www.mdpi.com/1718-7729/29/9/520

Internet

https://www.mdpi.com/1718-7729/29/9/520

Similar Items